2 results
Approved WMOPending
The goal of this trial is to find the best available conservative treatment, based on subjective pain scores, for children with Sever*s disease. Our primary objective is to score the possible decrease of pain experienced by the subjects. This will…
Approved WMOCompleted
Cohort 1 (HER2-positive/amplified MBC): MCLA-128 + trastuzumab ± vinorelbine Primary objective:• Evaluate efficacy of MCLA-128 combined with trastuzumab ± vinorelbine in terms of clinical benefit rate (CBR) at 24 weeks based on RECIST 1.1 (per…